NASDAQ:TNYA Tenaya Therapeutics (TNYA) Stock Price, News & Analysis $0.64 -0.01 (-1.88%) Closing price 04:00 PM EasternExtended Trading$0.63 -0.01 (-1.93%) As of 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tenaya Therapeutics Stock (NASDAQ:TNYA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tenaya Therapeutics alerts:Sign Up Key Stats Today's Range$0.62▼$0.6750-Day Range$0.44▼$1.4752-Week Range$0.39▼$5.32Volume2.41 million shsAverage Volume2.11 million shsMarket Capitalization$56.18 millionP/E RatioN/ADividend YieldN/APrice Target$6.25Consensus RatingBuy Company OverviewTenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Read More… Remove Ads Tenaya Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreTNYA MarketRank™: Tenaya Therapeutics scored higher than 71% of companies evaluated by MarketBeat, and ranked 266th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingTenaya Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTenaya Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Tenaya Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Tenaya Therapeutics are expected to grow in the coming year, from ($1.35) to ($1.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tenaya Therapeutics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tenaya Therapeutics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTenaya Therapeutics has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Tenaya Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.32% of the float of Tenaya Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenaya Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tenaya Therapeutics has recently increased by 7.70%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTenaya Therapeutics does not currently pay a dividend.Dividend GrowthTenaya Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.32% of the float of Tenaya Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenaya Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tenaya Therapeutics has recently increased by 7.70%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.70 News SentimentTenaya Therapeutics has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Tenaya Therapeutics this week, compared to 2 articles on an average week.Search Interest48 people have searched for TNYA on MarketBeat in the last 30 days. This is an increase of 30% compared to the previous 30 days.MarketBeat FollowsOnly 21 people have added Tenaya Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership5.0 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Tenaya Therapeutics insiders have bought 235,860.35% more of their company's stock than they have sold. Specifically, they have bought $24,999,999.00 in company stock and sold $10,595.00 in company stock.Percentage Held by Insiders32.76% of the stock of Tenaya Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.54% of the stock of Tenaya Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tenaya Therapeutics' insider trading history. Receive TNYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tenaya Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TNYA Stock News HeadlinesTop 3 Insider Stock Buys in March—Are They Still Good in April? (TNYA)March 25 at 9:18 AM | insidertrades.comGroup Gp Lp Column III Acquires 35,714,284 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) StockMarch 8, 2025 | insidertrades.comTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.March 26, 2025 | Porter & Company (Ad)Tenaya Therapeutics Publishes Positive Preclinical Data for TN-201 Gene Therapy Targeting MYBPC3-Associated Hypertrophic CardiomyopathyMarch 26 at 4:41 AM | nasdaq.comTenaya Therapeutics, Inc. (TNYA): Among Stocks Receiving the Most Insider Love in MarchMarch 25 at 1:04 PM | insidermonkey.comTenaya Therapeutics publishes preclinical data on TN-201 in cardiac functionMarch 24 at 4:51 PM | markets.businessinsider.comTenaya Therapeutics, Inc.'s (NASDAQ:TNYA) stock price dropped 13% last week; individual investors would not be happyMarch 24 at 11:51 AM | finance.yahoo.comTenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy ModelsMarch 24 at 8:30 AM | globenewswire.comSee More Headlines TNYA Stock Analysis - Frequently Asked Questions How have TNYA shares performed this year? Tenaya Therapeutics' stock was trading at $1.43 on January 1st, 2025. Since then, TNYA shares have decreased by 55.2% and is now trading at $0.6410. View the best growth stocks for 2025 here. How were Tenaya Therapeutics' earnings last quarter? Tenaya Therapeutics, Inc. (NASDAQ:TNYA) issued its earnings results on Monday, March, 17th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.04. When did Tenaya Therapeutics IPO? Tenaya Therapeutics (TNYA) raised $150 million in an initial public offering on Friday, July 30th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. Who are Tenaya Therapeutics' major shareholders? Top institutional investors of Tenaya Therapeutics include JPMorgan Chase & Co. (6.51%), Geode Capital Management LLC (1.60%), abrdn plc (0.76%) and Northern Trust Corp (0.60%). Insiders that own company stock include Group Gp Lp Column III, David V Goeddel, Deepak Srivastava, Faraz Ali, Timothy Hoey, Whittemore Tingley, Tomohiro Higa and Chihiro Saito. View institutional ownership trends. How do I buy shares of Tenaya Therapeutics? Shares of TNYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tenaya Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tenaya Therapeutics investors own include Voyager Therapeutics (VYGR), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings3/17/2025Today3/26/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TNYA CIK1858848 Webwww.tenayatherapeutics.com Phone650-825-6990FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Target$6.25 High Stock Price Target$9.00 Low Stock Price Target$5.00 Potential Upside/Downside+878.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-124,080,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-86.17% Return on Assets-71.14% Debt Debt-to-Equity RatioN/A Current Ratio5.27 Quick Ratio5.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.05 per share Price / Book0.31Miscellaneous Outstanding Shares87,583,000Free Float53,268,000Market Cap$55.97 million OptionableOptionable Beta2.83 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:TNYA) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.